Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

Objectives Currently published papers and clinical guidelines regarding the effects of
tocilizumab in severe and critical COVID-19 are contradictory. The aim of this meta-analysis …

Background To date, only dexamethasone has been shown to reduce mortality in
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …

Tocilizumab has been repurposed against the 'cytokine storm'in the setting of coronavirus
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …

This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the
treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May …

Abstract Background Coronavirus disease 2019 (COVID-19) has killed over 2.5 million
people worldwide, but effective care and therapy have yet to be discovered. We conducted …

Objectives Tocilizumab has been proposed as a candidate therapy for patients with severe
coronavirus disease 2019 (COVID-19), especially among those with higher systemic …

Introduction The results of studies of tocilizumab (TCZ) in COVID‐19 are contradictory. Our
study aims to update medical evidence from controlled observational studies and …